cerebral artery at base-line and after 30 s of breath holding. A breath-hold-index (BHI) of <0.69 indicates impaired cerebrovascular reserve capacity.

Results IMT in the aortic arch was higher in patents versus controls, 1.3±0.3 vs 1.1±0.2 mm (p=0.04), whereas no difference was found in the common carotid artery, 0.61 ±0.13 vs 0.55±0.10 mm (p=0.2). BHI-values were lower in the SLE-group, 1.29±0.36 vs 1.65±0.56 (p=0.05), whereas both groups had signs of preserved cerebrovascular reserve capacity. Mean oxygen saturation peak was decreased in SLE patients versus controls, 79.5±7.8% vs 86.9±5.6% (p=0.006). Endothelial function using EndoPAT did not differ, 0.72 ±0.40 vs 0.84±0.24, (p=0.3).

Conclusions This study indicates that microcirculatory vessel disease, as measured with EPOS and breath-hold index, could be present in SLE cases with atherosclerotic findings. However, the impaired microcirculation in SLE compared to population controls needs further validation in larger patient groups, also including non-atherosclerotic cases with SLE.

Funding Source(s): This work was supported by grants from the Swedish Rheumatism Association, the County Council of Östergötland, the Swedish Society of Medicine, the King Gustaf Vs 80 year anniversary foundation and the King Gustaf V and Queen Victorias Freemasons foundation.

Dynamic Diffuse Optical Spectroscopy Can Diagnose and Quantify Lupus Arthritis

Background SLE arthritis is difficult to evaluate because of the sometimes-evanescent nature of the symptoms and limitations of physical exams and imaging studies. Dynamic diffuse optical spectroscopy (dDOS) can be used to assess changes in light absorption through tissues during transient venous occlusion. The optical signal reflects changes in blood perfusion and has diagnostic value in rheumatoid arthritis. The current study explored the use of dDOS in SLE arthritis.

Methods 12 SLE patients (ACR criteria) with active arthritis and 5 controls were evaluated. A dDOS sensor module was developed (figure. 1a). Hemodynamic effects were obtained by inflating a BP cuff to 40 mmHg ×60 s. Light at 3 wavelengths (\(\lambda=530\), 655, 940 nm) was used to illuminate joints at 8 different points. Transmitted light intensities were measured with Si-photodetectors at 8 other positions (total 8×8×3=192 signal traces). Swollen, tender and healthy joints were examined by the same assessor.

Results SLE patients and normal controls dDOS data were available for analysis from 66 and 24 proximal interphalangeal (PIP) joints, respectively (PIPs 2–4). Best results were obtained at 530 nm with cuff inflation at 40 mmHg. A representative measurement of 3 SLE arthritis and 3 normal joints is shown in figure 1b, highlighting differences in rise and plateau time. Given the pronounced effects at \(\lambda=530\) nm, we speculate that altered vessel physiology paired with already-increased blood pooling in the affected inflamed joints resulted in quicker increase in light absorption (rise time) that is maintained longer (plateau time) compared to normal joints. The AUC for dDOS was consistent with excellent discrimination, AUC=0.8639, sensitivity=76.19, specificity=88.57 (figure 1c).

Conclusions dDOS can evaluate SLE arthritis with high sensitivity and specificity. Rise and plateau time of the optical traces correlate strongly with swollen and tender joint count. The advantages of dDOS are non-invasiveness, objectivity...
(eliminates inter-rater variability and operator dependency), low cost, and high speed of performance (~5 min per area of scanning) compared to US and MRI. dDOS has the potential to bring much-needed objectivity to the quantification of SLE arthritis.

Funding Source(s): N/A

**Background**

XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Co-ligation of CD19 and FcγRIIb inhibits B lineage cells key to lupus pathogenesis. This Phase 2 study in SLE was designed to minimize background medications and placebo responses to improve interpretation of a small trial in a complex, heterogeneous disease.

**Methods**

Patients were enrolled with active, non-organ threatening disease, and treated until improved with 160 mg of IM Depo-Medrol. Immunosuppressive drugs were withdrawn except antimalarials or 10 mg/day prednisone or equivalent before randomization to IV XmAb5871 (5 mg/kg) or placebo. Study treatments were given Q14 days until Day 225 or loss of improvement (LOI), defined as SLEDAI increase 4 points OR new BILAG A or B, with investigator-rated clinical significance. At LOI, patients resumed standard of care. The primary endpoint was the proportion of subjects without LOI by Day 225 in the efficacy evaluable group (those who completed Day 225 or discontinued due to LOI or a drug-related adverse event). Patients who withdrew for other reasons were excluded from this analysis.